FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2948018889> ?p ?o ?g. }

• W2948018889 abstract "e12070 Background: In triple negative breast cancer (TNBC), anti-PD-L1 is associated with gains in overall survival, however only in tumors with > 1% PD-L1+ ICs. Locoregional cytokine therapy is being evaluated as a method of priming and redirecting ICs to tumors, which may increase I-O benefit particularly in PD-L1 negative tumors. We report a sensitive method of quantifying I-O-related changes in PD-L1 and ICs using mIHC and single-cell hierarchical regression, which controls for within-tumor and across-patient PD-L1/IC heterogeneity. Methods: Pre-treatment and resection tissues from a phase Ib trial of locoregional cytokines (IRX-2, n = 16 subjects) in ESBC were analyzed. IRX-2 contains immunostimulatory cytokines (GM-CSF, IL-2, IFN-α, INF-γ, and IL-12) and was injected in peri-areolar tissue, which communicates directly with tumor-draining lymphatics. Specimens were analyzed for 1) H&E stromal TILs score; 2) clinical PD-L1 IC expression (Ventana SP142, 2 blinded pathologists); and 3) mIHC (PerkinElmer Vectra). InForm software was used to obtain geospatial outputs of tumor cells (CK+) and ICs (CD3, CD8, CD163) across multiple regions of interest (mean:18; range: 9-32). Mixed-effects modeling was used to evaluate for changes in PD-L1, ICs, and IC/tumor distance metrics. Results: PD-L1 and IC quantity by mIHC was highly concordant with clinical PD-L1 IC classification (JT test = 211, p < .001) and TIL score (r = 0.77). Cytokine therapy was associated with higher PD-L1 IC classification in 9/13 tumors, and increased PD-L1 ICs by mIHC in 14/15 (+337%, 95% CI: 120,769%). After adjusting for heterogeneity, cytokine therapy increased CD3+CD8+ ICs (+173%, CI: 93,287%) and CD3+CD8- ICs (+120%, CI: 21,301%). Therapy was also associated with increased effector-helper T-cell clustering (nearest-neighbor distance, -40%, CI: -29,-50%) and effector cell tumor localization (stromal-tumor interface CD8+ density +90%, Cl: 74, 305%). Conclusions: Our method is concordant with clinical PD-L1 and sTILs scores, and can additionally quantify IC and IC distances. This assay may allow for comparative I-O assessments with increased resolution, and will be used in a randomized phase II trial of pembrolizumab, chemo +/- IRX-2 in stage II/III TNBC." @default.
• W2948018889 created "2019-06-07" @default.
• W2948018889 creator A5003460413 @default.
• W2948018889 creator A5006880079 @default.
• W2948018889 creator A5009236755 @default.
• W2948018889 creator A5012793917 @default.
• W2948018889 creator A5015332254 @default.
• W2948018889 creator A5017531113 @default.
• W2948018889 creator A5021063127 @default.
• W2948018889 creator A5025100380 @default.
• W2948018889 creator A5025569977 @default.
• W2948018889 creator A5032916160 @default.
• W2948018889 creator A5034225982 @default.
• W2948018889 creator A5034928037 @default.
• W2948018889 creator A5042909616 @default.
• W2948018889 creator A5046908034 @default.
• W2948018889 creator A5047620654 @default.
• W2948018889 creator A5049502398 @default.
• W2948018889 creator A5064942066 @default.
• W2948018889 creator A5065814837 @default.
• W2948018889 creator A5080158021 @default.
• W2948018889 creator A5083855375 @default.
• W2948018889 date "2019-05-20" @default.
• W2948018889 modified "2023-09-25" @default.
• W2948018889 title "Evaluation of immunotherapy (I-O)-associated immune cell (IC) dynamics and PD-L1 expression using multispectral immunohistochemistry (mIHC) and single-cell hierarchical regression modeling in early-stage breast cancer (ESBC)." @default.
• W2948018889 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e12070" @default.
• W2948018889 hasPublicationYear "2019" @default.
• W2948018889 type Work @default.
• W2948018889 sameAs 2948018889 @default.
• W2948018889 citedByCount "0" @default.
• W2948018889 crossrefType "journal-article" @default.
• W2948018889 hasAuthorship W2948018889A5003460413 @default.
• W2948018889 hasAuthorship W2948018889A5006880079 @default.
• W2948018889 hasAuthorship W2948018889A5009236755 @default.
• W2948018889 hasAuthorship W2948018889A5012793917 @default.
• W2948018889 hasAuthorship W2948018889A5015332254 @default.
• W2948018889 hasAuthorship W2948018889A5017531113 @default.
• W2948018889 hasAuthorship W2948018889A5021063127 @default.
• W2948018889 hasAuthorship W2948018889A5025100380 @default.
• W2948018889 hasAuthorship W2948018889A5025569977 @default.
• W2948018889 hasAuthorship W2948018889A5032916160 @default.
• W2948018889 hasAuthorship W2948018889A5034225982 @default.
• W2948018889 hasAuthorship W2948018889A5034928037 @default.
• W2948018889 hasAuthorship W2948018889A5042909616 @default.
• W2948018889 hasAuthorship W2948018889A5046908034 @default.
• W2948018889 hasAuthorship W2948018889A5047620654 @default.
• W2948018889 hasAuthorship W2948018889A5049502398 @default.
• W2948018889 hasAuthorship W2948018889A5064942066 @default.
• W2948018889 hasAuthorship W2948018889A5065814837 @default.
• W2948018889 hasAuthorship W2948018889A5080158021 @default.
• W2948018889 hasAuthorship W2948018889A5083855375 @default.
• W2948018889 hasConcept C121608353 @default.
• W2948018889 hasConcept C126322002 @default.
• W2948018889 hasConcept C142724271 @default.
• W2948018889 hasConcept C143998085 @default.
• W2948018889 hasConcept C146357865 @default.
• W2948018889 hasConcept C1491633281 @default.
• W2948018889 hasConcept C151730666 @default.
• W2948018889 hasConcept C203014093 @default.
• W2948018889 hasConcept C204232928 @default.
• W2948018889 hasConcept C2777701055 @default.
• W2948018889 hasConcept C2781053074 @default.
• W2948018889 hasConcept C502942594 @default.
• W2948018889 hasConcept C530470458 @default.
• W2948018889 hasConcept C54355233 @default.
• W2948018889 hasConcept C71924100 @default.
• W2948018889 hasConcept C86803240 @default.
• W2948018889 hasConcept C8891405 @default.
• W2948018889 hasConceptScore W2948018889C121608353 @default.
• W2948018889 hasConceptScore W2948018889C126322002 @default.
• W2948018889 hasConceptScore W2948018889C142724271 @default.
• W2948018889 hasConceptScore W2948018889C143998085 @default.
• W2948018889 hasConceptScore W2948018889C146357865 @default.
• W2948018889 hasConceptScore W2948018889C1491633281 @default.
• W2948018889 hasConceptScore W2948018889C151730666 @default.
• W2948018889 hasConceptScore W2948018889C203014093 @default.
• W2948018889 hasConceptScore W2948018889C204232928 @default.
• W2948018889 hasConceptScore W2948018889C2777701055 @default.
• W2948018889 hasConceptScore W2948018889C2781053074 @default.
• W2948018889 hasConceptScore W2948018889C502942594 @default.
• W2948018889 hasConceptScore W2948018889C530470458 @default.
• W2948018889 hasConceptScore W2948018889C54355233 @default.
• W2948018889 hasConceptScore W2948018889C71924100 @default.
• W2948018889 hasConceptScore W2948018889C86803240 @default.
• W2948018889 hasConceptScore W2948018889C8891405 @default.
• W2948018889 hasLocation W29480188891 @default.
• W2948018889 hasOpenAccess W2948018889 @default.
• W2948018889 hasPrimaryLocation W29480188891 @default.
• W2948018889 hasRelatedWork W1586178471 @default.
• W2948018889 hasRelatedWork W2057186227 @default.
• W2948018889 hasRelatedWork W2509486054 @default.
• W2948018889 hasRelatedWork W2528220687 @default.
• W2948018889 hasRelatedWork W2569158635 @default.
• W2948018889 hasRelatedWork W2582960575 @default.
• W2948018889 hasRelatedWork W2590179977 @default.
• W2948018889 hasRelatedWork W2757328282 @default.
• W2948018889 hasRelatedWork W2790603825 @default.
• W2948018889 hasRelatedWork W2804392795 @default.
• W2948018889 hasRelatedWork W2807753880 @default.
• W2948018889 hasRelatedWork W2898222983 @default.

• next